Contralateral breast cancer after limited surgery plus radiotherapy of early mammary tumors.
R Zucali(Fondazione IRCCS Istituto Nazionale dei Tumori), Umberto Veronesi(Fondazione IRCCS Istituto Nazionale dei Tumori), Enrico Sverzellati(Fondazione IRCCS Istituto Nazionale dei Tumori), C. Stucchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto Banfi(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto Luini(Institute for Experimental Endocrinology and Oncology), Virgilio Sacchini(Memorial Sloan Kettering Cancer Center)
PubMed
October 1, 1987
Cited by 32
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Breast Cancer
|New England Journal of Medicine|1992|701
Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
|New England Journal of Medicine|1977|667
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606